1-cyclopropyl-1H-pyrazole-4-sulfonylchloride | 1781437-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-cyclopropyl-1H-pyrazole-4-sulfonylchloride
• 英文别名: 1-cyclopropylpyrazole-4-sulfonyl chloride
• CAS: 1781437-05-5
• 化学式: C₆H₇ClN₂O₂S
• 分子量: 206.65
• InChiKey: OBXUZFCVGNBVLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS<br/>[FR] DÉRIVÉS HÉTÉROARYLDIHYDROPYRIMIDINE ET MÉTHODES DE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019001420A1

  公开（公告）日：2019-01-03

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了一些用于治疗HBV感染的化合物，以及其药物组合物和抑制、抑制或预防受试者HBV感染的方法。
• Compounds
  申请人：Inflazome Limited

  公开号：US11530200B2

  公开（公告）日：2022-12-20

  The present invention relates to compounds of formula (I), wherein Q is selected from O or S; R 1 is a 5- or 6-membered heteroaryl group consisting of one or more carbon atoms, and one or more nitrogen and/or oxygen atoms, and substituted with a monovalent, optionally substituted cycloalkyl, cycloalkenyl or heterocyclic group, wherein the 5- or 6-membered heteroaryl group of R 1 may optionally be further substituted; R 2 is an α,α′-substituted cyclic group which may optionally be further substituted; R 3 and R 4 are each independently hydrogen, halogen, —OH, —NH 2 , —CN, —R 5 , —OR 5 , —NHR 5 or —N(R 5 ) 2 ; or R 3 and R 4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R 5 is independently an optionally substituted C 1 -C 4 alkyl group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及式（I）化合物，其中 Q 选自 O 或 S；R 1 是由一个或多个碳原子、一个或多个氮原子和/或氧原子组成的 5 或 6 元杂芳基，并被一个单价的、任选取代的环烷基、环烯基或杂环基取代，其中 R 1 的 5 或 6 元杂芳基 1 可任选被进一步取代 2 是 α、α′-取代的环基，可任选被进一步取代； R 2 3 和 R 4 各自独立地为氢、卤素、-OH、-NH 2 、-CN、-R 5 、-OR 5 ，-NHR 5 或-N(R 5 ) 2 或 R 3 和 R 4 连同它们所连接的碳原子可形成一个 3 至 7 元饱和或不饱和、任选取代的环状基团；以及 R 5 独立地为任选取代的 C 1 -C 4 烷基。本发明进一步涉及这类化合物的盐、溶液剂和原药，涉及包含这类化合物的药物组合物，涉及这类化合物在治疗和预防医学紊乱和疾病中的用途，特别是通过抑制 NLRP3。
• HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Janssen Pharmaceutica NV

  公开号：EP3645516A1

  公开（公告）日：2020-05-06
• NOVEL COMPOUNDS
  申请人：Inflazome Limited

  公开号：US20210002274A1

  公开（公告）日：2021-01-07

  The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R 1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R 2 is a cyclic group substituted at the a and a′ positions, wherein the substituent at the α-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; R 3 and R 4 are each independently hydrogen, halogen, —OH, —NH 2 , —CN, —R 5 , —OR 5 , —NHR 5 or —N(R 5 ) 2 ; or R 3 and R 4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R 5 is independently optionally substituted C 1 -C 4 alkyl. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.